Zydus Cadila's EBIDTA crosses mark of Rs. 30 bn

Ahmedabad, May 27th, 2021

Announcing the results for the fourth quarter and full year ended March 31st, 2021, Zydus Cadila registered Total Income from operations of Rs. 3,847 crores, for the fourth quarter, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year. Earnings before Interest, Depreciation and Tax (EBIDTA) grew by 8% on a y-o-y basis to Rs. 855 crores during the fourth quarter. Net Profit was up by 73% on a y-o-y basis to Rs. 679 crores during the fourth quarter. For the year ended March 31st, 2021, on a consolidated basis, the Company registered the Total Income from operations of Rs. 15,102 crores, up by 6%. The Company achieved new milestones in terms of EBIDTA and Net Profit in the year. The EBIDTA for the year of Rs. 3,341 crores registered 20% growth over the previous year. Net Profit for the year was Rs. 2,134 crores.

The Company's business in India geography which comprises Human health formulations business, Consumer wellness business and Animal health business posted a strong growth during the quarter as it grew by 18% on a y-o-y basis and registered revenues of Rs. 1,772 crores. Human health formulations business in India grew by 15% and Consumer wellness business grew by 22% on a y-o-y basis during the quarter.

US formulations business registered revenues of Rs. 1,509 crores during the quarter. Strengthening its regulatory pipeline, the Company filed 22 additional ANDAs during the year with the USFDA, taking the cumulative filings to 412. The Company received 35 ANDAs approvals during the year, taking the total to 317 product approvals.

Continuing with its relentless efforts on the battling COVID with diagnostics, therapeutics and vaccines, the company launched Virafin (Pegylated Interferon alpha-2b (PegIFN) to treat moderate infection in adult COVID-19 patients during the quarter. ZyCoV-D, the Company's plasmid DNA vaccine is at an advanced stage of Phase III clinical trials and the data is expected to be submitted to the regulators in June.

Making headway in its innovation programme, the company completed the patient enrolment in DREAM-ND and DREAM-D Phase III trials of Desidustat in India, an oral small molecule hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for treatment of anaemia in patients with Chronic Kidney Disease (CKD) during the year.

Furthering its strides to bridge unmet healthcare needs, the company also received the approval for Saroglitazar Mg, for the treatment of Non Alcoholic Fatty Liver Disease (NAFLD). With this Saroglitazar Mg is now indicated for both NAFLD and Non-Alcoholic Steatohepatitis (NASH). Saroglitazar Mg which is also evaluated for the treatment of Primary Biliary Cholangitis (PBC), was given the 'Fast Track Designation' also received the Orphan Drug Designation from the USFDA. During the year, the Company made a presentation of Saroglitazar in NAFLD at the American Association for the study of Liver Diseases (AASLD), Boston.

###

For further information please contact :
The Corporate Communications Department

Cadila Healthcare Limited
Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481, India.
Phone : +91-079-71800000, +91-079-48040000 www.zyduscadila.com
CIN : L24230GJ1995PLC025878